Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis

Gavin Giovannoni; Stuart Cook; Kottil Rammohan; Peter Rieckmann; Per Soelberg Sørensen; Patrick Vermersch; Anthony Hamlett; Vissia Viglietta; Steven Greenberg; CLARITY Study Group

doi:10.1016/S1474-4422(11)70023-0

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis

Gavin Giovannoni, Stuart Cook, Kottil Rammohan, Peter Rieckmann, Per Soelberg Sørensen, Patrick Vermersch, Anthony Hamlett, Vissia Viglietta, Steven Greenberg, CLARITY Study Group

Department of Neurology

204 Citations (Scopus)

Abstract

On the basis of various clinical and MRI measurements, the phase 3 Cladribine Tablets Treating Multiple Sclerosis Orally (CLARITY) study in patients with relapsing-remitting multiple sclerosis (RRMS) showed that short-course oral treatment with cladribine at cumulative doses of 3·5 and 5·25 mg/kg over 96 weeks was more effective than placebo. Achieving sustained freedom from disease activity is becoming a viable treatment goal in RRMS; we therefore aimed to assess the effects of cladribine on this composite outcome measure by doing a post-hoc analysis of data from the CLARITY study.

Original language	English
Journal	Lancet neurology
Volume	10
Issue number	4
Pages (from-to)	329-37
Number of pages	9
ISSN	1474-4422
DOIs	https://doi.org/10.1016/S1474-4422(11)70023-0
Publication status	Published - 2011

Keywords

Cladribine
Disease-Free Survival
Humans
Immunosuppressive Agents
Multiple Sclerosis, Relapsing-Remitting
Odds Ratio
Randomized Controlled Trials as Topic
Treatment Outcome

Access to Document

10.1016/S1474-4422(11)70023-0

Cite this

Giovannoni, G., Cook, S., Rammohan, K., Rieckmann, P., Sørensen, P. S., Vermersch, P., Hamlett, A., Viglietta, V., Greenberg, S., & CLARITY Study Group (2011). Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Lancet neurology, 10(4), 329-37. https://doi.org/10.1016/S1474-4422(11)70023-0

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. / Giovannoni, Gavin; Cook, Stuart; Rammohan, Kottil et al.
In: Lancet neurology, Vol. 10, No. 4, 2011, p. 329-37.

Research output: Contribution to journal › Journal article › Research › peer-review

Giovannoni, G, Cook, S, Rammohan, K, Rieckmann, P, Sørensen, PS, Vermersch, P, Hamlett, A, Viglietta, V, Greenberg, S & CLARITY Study Group 2011, 'Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis', Lancet neurology, vol. 10, no. 4, pp. 329-37. https://doi.org/10.1016/S1474-4422(11)70023-0

@article{46922ab0ad1a4440bd457204828c7922,

title = "Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis",

abstract = "On the basis of various clinical and MRI measurements, the phase 3 Cladribine Tablets Treating Multiple Sclerosis Orally (CLARITY) study in patients with relapsing-remitting multiple sclerosis (RRMS) showed that short-course oral treatment with cladribine at cumulative doses of 3·5 and 5·25 mg/kg over 96 weeks was more effective than placebo. Achieving sustained freedom from disease activity is becoming a viable treatment goal in RRMS; we therefore aimed to assess the effects of cladribine on this composite outcome measure by doing a post-hoc analysis of data from the CLARITY study.",

keywords = "Cladribine, Disease-Free Survival, Humans, Immunosuppressive Agents, Multiple Sclerosis, Relapsing-Remitting, Odds Ratio, Randomized Controlled Trials as Topic, Treatment Outcome",

author = "Gavin Giovannoni and Stuart Cook and Kottil Rammohan and Peter Rieckmann and S{\o}rensen, {Per Soelberg} and Patrick Vermersch and Anthony Hamlett and Vissia Viglietta and Steven Greenberg and {CLARITY Study Group}",

year = "2011",

doi = "10.1016/S1474-4422(11)70023-0",

language = "English",

volume = "10",

pages = "329--37",

journal = "Lancet neurology",

issn = "1474-4422",

publisher = "The/Lancet Publishing Group",

number = "4",

}

TY - JOUR

T1 - Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis

AU - Giovannoni, Gavin

AU - Cook, Stuart

AU - Rammohan, Kottil

AU - Rieckmann, Peter

AU - Sørensen, Per Soelberg

AU - Vermersch, Patrick

AU - Hamlett, Anthony

AU - Viglietta, Vissia

AU - Greenberg, Steven

AU - CLARITY Study Group

PY - 2011

Y1 - 2011

N2 - On the basis of various clinical and MRI measurements, the phase 3 Cladribine Tablets Treating Multiple Sclerosis Orally (CLARITY) study in patients with relapsing-remitting multiple sclerosis (RRMS) showed that short-course oral treatment with cladribine at cumulative doses of 3·5 and 5·25 mg/kg over 96 weeks was more effective than placebo. Achieving sustained freedom from disease activity is becoming a viable treatment goal in RRMS; we therefore aimed to assess the effects of cladribine on this composite outcome measure by doing a post-hoc analysis of data from the CLARITY study.

AB - On the basis of various clinical and MRI measurements, the phase 3 Cladribine Tablets Treating Multiple Sclerosis Orally (CLARITY) study in patients with relapsing-remitting multiple sclerosis (RRMS) showed that short-course oral treatment with cladribine at cumulative doses of 3·5 and 5·25 mg/kg over 96 weeks was more effective than placebo. Achieving sustained freedom from disease activity is becoming a viable treatment goal in RRMS; we therefore aimed to assess the effects of cladribine on this composite outcome measure by doing a post-hoc analysis of data from the CLARITY study.

KW - Cladribine

KW - Disease-Free Survival

KW - Humans

KW - Immunosuppressive Agents

KW - Multiple Sclerosis, Relapsing-Remitting

KW - Odds Ratio

KW - Randomized Controlled Trials as Topic

KW - Treatment Outcome

U2 - 10.1016/S1474-4422(11)70023-0

DO - 10.1016/S1474-4422(11)70023-0

M3 - Journal article

C2 - 21397565

SN - 1474-4422

VL - 10

SP - 329

EP - 337

JO - Lancet neurology

JF - Lancet neurology

IS - 4

ER -

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis

Abstract

Keywords

Access to Document

Fingerprint

Cite this